Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Non-interventional, Single Arm Study Investigating Long-term Glycaemic Control in Patients With Type 2 Diabetes Initiating Xultophy® (IDegLira) in a Realworld Setting in Italy

Next Previous
X
Search
Trial Profile

A Prospective, Non-interventional, Single Arm Study Investigating Long-term Glycaemic Control in Patients With Type 2 Diabetes Initiating Xultophy® (IDegLira) in a Realworld Setting in Italy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec/liraglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms REX
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 18 Jan 2023 Status changed from active, no longer recruiting to completed.
    • 19 Oct 2022 Status changed from recruiting to active, no longer recruiting.
    • 18 Jun 2022 Trial design and results of the interim analysis performed to describe baseline clinical characteristics of patients at the time of IDegLira treatment initiation and the reasons for the choice of IDegLira treatment published in the Diabetes Therapy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top